Immutep is well-positioned in the immunotherapy market, with a strong pipeline and a focus on collaborations and robust clinical trials.
Bears say
Immutep is a biotechnology company with a negative outlook due to its high clinical development risk and regulatory risk, as well as its dependence on the success of eftilagimod alfa (efti) in its Phase 3 trial for 1L non-small cell lung cancer (NSCLC). Additionally, while the company has a diversified product portfolio, it has a small addressable market and faces competition from other immunotherapy treatments in the same space. Furthermore, the company's stock is subject to sector risk and may decrease in value even if it meets or exceeds investor expectations.
Immutep Ltd (IMMP) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Get the latest Immutep Ltd (IMMP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Analysts have given Immutep Ltd (IMMP) a Hold based on their latest research and market trends.
According to 2 analysts, Immutep Ltd (IMMP) has a Hold consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
Get the latest Immutep Ltd (IMMP) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.